6MOA image
Deposition Date 2018-10-04
Release Date 2019-01-23
Last Version Date 2024-03-13
Entry Detail
PDB ID:
6MOA
Title:
C-terminal bromodomain of human BRD2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1H-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.27 Å
R-Value Free:
0.17
R-Value Work:
0.16
R-Value Observed:
0.16
Space Group:
P 2 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 2
Gene (Uniprot):BRD2
Chain IDs:A
Chain Length:110
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
Bioorg. Med. Chem. 27 457 469 (2019)
PMID: 30606676 DOI: 10.1016/j.bmc.2018.11.020

Abstact

The bromodomain and extra-terminal (BET) family of proteins, consisting of the bromodomains containing protein 2 (BRD2), BRD3, BRD4, and the testis-specific BRDT, are key epigenetic regulators of gene transcription and has emerged as an attractive target for anticancer therapy. Herein, we describe the discovery of a novel potent BET bromodomain inhibitor, using a systematic structure-based approach focused on improving potency, metabolic stability, and permeability. The optimized dimethylisoxazole aryl-benzimidazole inhibitor exhibited high potency towards BRD4 and related BET proteins in biochemical and cell-based assays and inhibited tumor growth in two proof-of-concept preclinical animal models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures